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Transurethral microwave thermotherapy: an evolving 
technology in the treatment of benign prostatic enlargement
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History
The use of heat in the treatment of prostatic diseases 
has been advocated for over a century. In 1866 Busch 
showed that malignant tissue was especially susceptible
Currently, the application of high energy thermotherapy 
in the treatment of BPH is being evaluated.
Microwave tissue interaction
to heat [1]. Since then, many different and ingenious The applicability and outcome of microwave treatment 
methods for the beneficial application of heat have been is influenced by the microwave frequency used, the
described.
In prostatic tissue there are several temperature 
thresholds: below 40°C cells are affected little; between 
41 and 45°C malignant cells are more susceptible to 
permanent damage than benign tissue and this effect is 
termed hyperthermia: in the range 45-6C)°C cell death 
can occur and is defined as thermotherapy. Thermal 
treatment in excess of 70°C destroys all living human 
tissue and is termed thermoablation [2|.
Hyperthermia was first introduced in the early 1980s, 
initially to treat prostate carcinoma [ 3|. The alleviation
tissue composition and vascularization, and the patient’s 
tolerance of the heat treatment.
The appropriate electromagnetic spectrum comprises 
microwaves in the range from 300 to 3000 MHz but the 
two frequencies most commonly used are 9.15 MHz and 
1296 MHz. When applied transurethrally, the isothermic 
field of the latter shows a concentric heat distribution 
more or less Mowing the anatomical borders of the 
transition zone of the, prostate and not reaching the 
maximum temperature in the rectal mucosa; 
quency thus seems best fitted for the treatment of prostatic
of the symptoms of prostatism and the reduction of diseases. The effects of microwaves on tissue depends on
tumour bulk seen in patients treated with hyperthermia 
also led to the application of hyperthermia in patients 
with benign prostatic hyperplasia (BPH) [4]. Many stud­
ies have been published on the use of hyperthermia in 
the treatment of BPH. Although they reported significant
improvementetiect on
was very limited. Moreover, in a multicentre study [5], 
transrectal hyperthermia was shown to be ineffective
jTK and
greater in fat, which has a high water content, than in 
muscle, which has a lower water content. The depth of 
penetration also depends on the microwave frequency:
higher the fr ! less the penetri
ever, penetration is also influenced by tissue temperature 
and refraction, reflection and dispersion oí'the microwaves 
in heterogenous tissue. Furthermore, heat conduction and
when compared 
transurethral hyperthermia is still under investigation 
as it has proved to be more effective than the transrectal 
route and better than sham treatment [6,7]. The results 
achieved with hyperthermia suggested that higher tem­
peratures would be more effective. Transurethral micro­
wave thermotherapy (TUMT) was to apply
convection are influenced by of the
causing spatial differences in tissue temperature.
Cell death is achieved when temperatures exceed the 
cytotoxic threshold, which depends on cell type; in
idenomatous tissue the thermal threshold is 
45°C for 30 min. Therefore, when heterogenous tissue 
is treated, not all cells within the treated area will die.
microwave energy deep within the lateral prostatic lobes Furthermore, small capillaries are thrombosed, whereas
whilst simultaneously the
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mucosa. larger vessels are spared because they are cooled by
blood flow. Thus, the size of the necrotic area is deter­
mined not only by tissue composition but also by tissue
Accepted for publication 9 May 1995 vascularization [2].
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To allow treatment with no anaesthesia, heating of Version 2.0 is the most widely used and Version 2.5 is
the urethral mucosa, which is rich in pain receptors, 
should be avoided because 45"C is not only the thermo- 
toxic level but also the thermal pain threshold 
transition zone of the prostate has fewer 
can therefore be heated to more than 45°C. Urethral 
obstruction associated with BPH arises from anatomical 
compression by the periurethral adenomatous tissue, 
from the bladder neck to the verumontanum, and partly 
by a dynamic obstruction resulting from the tone of the
currently under investigation. The procedure for TUMT 
treatment has 'S C I'
1 1 1 , 1 2 ]
The results of Prostatron treatment are 
below.
TUMT usina Prostasoft® 2.0
, over 25 000 patients with BPH have been
prostatic smooth muscle [8]. Theoretically, the optimal treated with the Prostatron device using Prostasoft® 2.0. 
treatment is one that spares the urethral mucosa, heats The first clinical data was presented by Devonec et al
the periurethral prostate tissue to above cytotoxic tem-
in d adjacent rectal mucosa
and Carter et al. in 1991 [11,13]. The results achieved 
for symptomatic improvement and changes in urinary
performance wereThermotherapy with urethral cooling allows not only 
the delivery of increased energy but also higher tempera­
tures, up to 70°C, deep inside the lateral prostatic lobes, 
resulting in tissue coagulation, necrosis and even tissue siderable improvement
and impressive. The
overall symptomatic changes, using the total Madsen
symptom score, s
ablation. Not all prostates reach the maximum tempera­
ture intended, because the thermoregulation of the tissue
usually 13 (range 11-16) and the expected outcome at
3 months is about 4 (range i an overall
differs [9]. Studies correlating the achieved intraprostatic improvement of about 70% (Table 1). Similar symptom 
temperatures and outcome of treatment suggest that the scores were found in asymptomatic elderly men [15 ].
higher the intraprostatic temperature, the better the 
clinical results [10].
Thus the clinical benefit and tolerability of TUMT must 
be related to the achieved intraprostatic temperature, 
which results from a complex interaction between the 
biological response to microwaves, the pattern of energy 
provided during the treatment and the incorporation of 
urethral cooling.
Urinary peak flow rates (Qrnax.) were also improved, 
although less pronounced. Mean Qmax at baseline was
about 9 mL/s (range 8,2-10.4), improving by 3-4 mL/s 
after 3 months, representing a mean improvement of 
35% over baseline. Unlike
impr 
had
s in Qmax occurred gradually.
by 4 weeks after treatment and was more
#•
c 3 of
Qmax occurred between 6 and 12 months 'c ;r TUMT
Clinical results
*< was sustained at the follow-up 3 years later 116,1 n
-void residual urine (PVR) also decreased
Many thermotherapy devices have been developed for significantly; large initial PVRs were reduced, but better
the treatment of BPH, including the llrowave (Dornier 
Medical Systems, Germering, Germany), ECP (Prof. H. T varii
in patients with a PVR of <200 mL. 
objective outcome between the different
I>
Medical A/S), T3 (IJrologix, Minneapolis, USA), TURAPY 
(Direx Medical Sytems, Petah Tiqvah, Israel) rC
•ntres was considerable.
2.0 are
the results of TUMT
placebo effect remain to
France). latter has been
be evaluated.
reported, and the authors have experience with over
600 patients treated using 
following section
device. Therefore,
treatment versus TUMT using Prostasoft * 2.0
possible ‘placebo’ effects and thus
device and compares the results with those a precise and general definition of ‘placebo’ is difficult, 
available from the other devices and with transurethral Broadly, the placebo effect could be defined as a single,
is inactive andresection of the prostate (TURP).
The Prostatron has been 
programs which have , mt m
ensuring maximum safety
no lor Version 1.0
unknowable nuisance varie 
spedile in its effect. To í to
of surgical intervention is a dari
There are several 
ment, of the
treat
use of thermotherapy for
18 ~“2 3), the majority of which s effect
(temperatures< SOT); Version 2.0 (temperatures from of TUMT on both subjective and objective
50“60"C) and sion 2.5 (temperatures ^  70' C). w leant placebo (Table 2). In
'O 1995 British journal of Urolomi 76, S 51 — S Î8
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Table 1 Improvement in main treatment indices before, }, 6 and 12 months after TUMT. Where available, means are shown with 
standard deviation
Referenc
No. of 
e, patients
Symptom score Omm (mL/s) Post-void residual volume (mL)
Baseline 3 months 1 year Baseline 3 months 1 year Baseline 3 months 1 year
[ 131 37 12 ±3.0 8 ±3.0 - 8.4±2.2 10.8 ±3.1 109 + 60 50 ±66 UMW
[11] 19 12 2.8 1.4 8.2 14.3 14.3 64 4 1 58
135] 37 8.5*±2.4 4.5 ±2.5 10.3 ±5,4 11.5 ±5 . 1 ~ UKJMf
[36; 60 13.9 4.8 DM« 8 .9 1 3. 1
[37] 17 16.5 ±4.4 — 6.9 7 > -I- ) l _i * + * JL, • * 10.7 ±3.0 39 ±50 — 1 7 ± 2 3
[38] 1 3 0 12.9 5.9 6.4 10.4 1 1.5 11.8 54 49 42
[39] 12 8 1 1.3 2.1 p u  i l l 9.2 14.9 r t i r * 100 4 3
[40J 140 11.7*± 5.0 4.9 ±3.3 4.2 9.0 ±4.2 12.6 ±4 .3 13.3 ± 4,0 1 3 5 ± 18 81 ±27 41 ±41
[41J 140 2 3.7* ±4.4 10.6 ±2.7 11.6 10.1 ±4,7 12.3 ±3 .2 12.4 ±3.4 98 ±46 69 ±29 76 ± 2 3
142] 818 13.3 5.7 3.5 8.8 13.0 12.6 M m m
143] 115 15.7 3.8 2.6 9 . 8 13 . 3 13.7 108 33 22.4
•Symptom score other than the Madsen-Iversen Symptom score
Table 2 Results of sham-controlled studies. Mean values with standard deviation where available
Symptom score Qfwu* Post-void residual urine (mL)
No. nf
Reference Treatment patients Baseline 3 months 1 year Baseline 3 months 1 year Baseline 3 months 1 year
[18] Sham 19 14.2 12.8 --------------- 8 .6 9.2 118 171 I M * >
TUMT 21 14.5 4.3 #  M l 8.5 13.0 M M H 147 12
[19] Sham 24 12.1 8.2 9 .1 9.7 9.5 11. 3 VsUiA * - " * 1
TUMT 24 .13.2 5.9 3.3 9.6 13.0 14.0 ■  l I X ^
[20] Sham 36 14.9 10.7 7.4 9.5 » S M f- Q tM é
TUMT 75 13.9 6.3 j —  ■ 7.3 11,5 N M W
122] Sham 44 12.9 ±3.1 10.4 ±4.7 8,2±4.5 9.6 ±2.7 9.7 ±3.3 ■10-5 ±4.3 85 ±68 104 ±94 56 ±65
TUMT 46 13.7 ±3.4 4.7 ± 3.7 4.2± 5.5 9.2±2.5 13.4 ±5.8 I 3.4± 5.2 94 ±75 34 ±47 50 + 48
123] Sham 40 17.5* 9.5 9.4±2.8 9.5 ±2.9 97 ±56 106 + 85
TUMT 40 19.0* 9.5 m m  1 8.8 ± 2.3 9.9 ±3.1 — 86 ±75 86 ±51
Control 40 18.0* 1 7.0 8.8±2.7 8.5 ±1.9 86±6 3 83 + 53
* American Urologie Association — 7 symptom score
addition, the changes in prostate-spedlic antigen
ils, seen only alter TUMT [19,20], are further proof 
that the mechanism of action of TUMT is related to the
thermal
mechanic
of prostatic tissue and not to the
:t of a single a  
to be considered as an
rization.
to surgical
therapy in (a subgroup of) patients with BPH, TIJMÌ 
should be compared with TURP.
TUMT using Prostasoft® 2.0 versus TURP
TUMT improved from a baseline of 12.1 to 
3.0 after 3 years of follow-up and from 13.6 to 2. 3 In
TURP. TUMT had less effect on voiding 
parameters; the mean Qm„x improved from a baseline of
8.4 mL/s to 11.9 mL/s 3 years after treatment in those
ire* by TUMT, whereas
8.3 mL/s to 18.6 mL/s. The 
decreased similarly in both groups, from a baseline of 
97 mL to 47 mL after 3 years in I
from 104 to 45 mL in the TURP group (Table 3). It was 
concluded that the objective improvements with TUMT
To evaluate the clinical utility of TUMT, Dahlstrand et al. were not equal to those with TURP, bût the subjective
standard’ improvements were more or less compar
[17]. Their study showed a statistically identical improve­
ment of symptom scores in patients treated with TUMT 
or TURP. This effect was sustained for at
achieve the 0max T
fHI
3 \s
of follow-up. The mean Madsen score in those patients
questioned, because asymptomatic age-ntu 
only have a mean Qmax of 13 mL/s [24],
It is clear that the mechanism of action of TUMT,
CD 1995 British Journal of Urology 76, 531-5 38
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Baseline 3 months
Madsen symptom score
TUMT 12.1 ±3.0 2.6 ±2.6
TURP 13.6 ±3.9 .1.1 ±2.8
Qmax (mL/s)
TUMT 8.4±2.6 11,5 ± 4.2
TURP 8.3 ±3.2 18.1 + 7.1
PVR (mL)
TUMT 97 ± 78 51 ±51
TURP 104 + 95 34 + 32
12 months 24 months i 6 months
2.3 ±2.4 2.3 ±2.9 3.0 ±2.9
0.6 ±1.4 1.2 ±1.8 2.3 ±3.7
12.3 ±4.1 12.3 ±4.4 11.9 ±3.4
18.9 ±6.0 17.6 ±5.9 18.6 ±7.1
55 ±65 47 ±43 42 ± 51
23 ± 18 27 ± 32 45 ±27
Table 3 Results of a randomized controlled 
study of TUMT versus TURP [17] (TUMT 
« = 38; TURP » = 32). Mean values with 
standard deviation
using the Prostasoft® 2.0 software, is substantially months :;i * 2d a cavity
different to that which produces the volume reduction in more than 40% of the patients. There was a positive 
and cavity formation obtained with TURP. Clinical out- correlation between the presence of such a cavity and 
come could possibly be enhanced with higher tempera- the improvement in Q 
tures, resulting in thermo-ablation and 
formation.
max *
cavity
Prostasoft® 2.5
Modifications to the operating software have provided 
more power at a maximum of 70 W and a higher rectal 
threshold temperature, resulting in fewer interruptions
Thus, more energy delivered to the prostate seems to 
result in a greater improvement in the objective param­
eters, possibly because cavities are created in the prostate. 
However, the price is an increased incidence of morbidity. 
Whereas patients treated using Prostasoft 2.0 were 
reported to have a urinary retention rate after treatment 
of about 20%, using high-energy Prostasoft 2.5 a cath­
eter was needed in all patients for at least 1 week.
during treatment and a mean increase of 40% in the Although irritative complaints such as frequency, dysu
total energy delivered to the prostate [25].
Changes in subjective parameters using (high-energy)
ria and haematuria were also reported after low-energy 
TUMT treatments, they were more frequent and pro-
Prostasoft® 2.5 were similar to those in patients treated nounced during the first 2-4 weeks in patients receiving
using Prosti 2.0. The mean Madsen symptom score
improved from a baseline of 14, to 6 at the 3-month 
follow-up. However, when objective improvement was 
compared, there was a significantly better outcome in 
the changes in Qmilx (Table 4) [25,261, Indeed, after high-
energy thermotherapy, values of Qm„x were greater than
those of patients in the same age group but with no 
voiding symptoms [24]. The improvements in Qmax
in the range that is observed after TURP, from a mean 
baseline of 9 mL/s to almost .1.6 mL/s by 3 
treatment. Transrectal ultrasonography of
the high-energy treatment. the high-
energy treatments are still possible on an out patient 
basis in a single 1-h session with no need for anaesthesia.
Selection criteria
clinical results of TUMT show a clear separation 
2en patients who respond favourably to TUMT in 
both subjective and objective parameters and patients 
who do not respond at all. Consequently, many investi-
'S have searched for selection criteria to predict
KWH*
Device
2 54M* J
TURAPY 70
Prostalund
T3 System
No.
of patients
OINfW
After
*»• flu w u m  i f in * n irtmip
improvement
I H k
[44]
[26]
116 
72
9.6
9.2
15.7
15.2
59
62
[45] 72 5.8 12.3 53
[46] 91 8.5 10.2 38
147] 103 9.4 14.3 62
Table 4 Some results obtained using 
energy thermotherapy devices t
stasoft® 2.5
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clinical outcome. Because high-energy TUMT is under 
clinical evaluation, no detailed selection criteria are yet 
available and the following study was initiated in patients 
treated with Prostasoft®1 2.0.
that no single subjective or objective parameter was
significantly correlated with outcome after
rs versus non-res
Data from 292 patients in 17 centres were ane 
retrospectively [27]. Using data obtained at the 6-month 
follow-up, patients were divided into responders, defined 
as having a Madsen symptom score ^3 , ^ c;nM/>
1 ^  "I I** *  / ^  N /W V i I
TUMT. However, there was a trend towards a better 
outcome in patients with less obstruction. Schäfer defined 
two types of obstruction, constrictive and compressive 
32]. When the patients were divided according to this 
definition, both groups were still comparable at baseline 
but differed significantly 
the symptoms of BPH was significantly modified in both
s, with a greater decrease in severity in patients
a
—... .... — ........... or > 50%
crease, a Qmnx >15 mL/s or > 5 0% improvement, and
<50 mL or >
with constriction than in those with compression. The
change in treatment also
50% improvement, and non- differed significantly in both groups;
r* a a Madsen symptom 
score > 8 or ^  50% improvement, a Qmax < 10 mL/s 
or <20% improvement, and a PVR >200 mL or< 50% 
decrease. There were no differences in any of the baseline 
clinical variables (i.e. age, prostate volume, symptom 
scores, Qmtlx and PVR) between the groups and it was 
concluded that none of the
nantly constrictive obstruction had a
in voiding parameters than 
compressive obstruction. It was c that PFA
be used to identify those patients who respond favourably
tO.
2 varie in
this study were able to define the ‘ideal’ patient for 
treatment or to predict the result of treatment. However,
Discussion
Since 1990, TUMT using Prostasoft® 2.0 has been used
compared with non-responders, the responders had sig- for the treatment of men with lower urinary tract
nificantly different curves of urethral and rectal tempera- symptoms. There are several advantages of the minimally
tures during treatment, possibly because there was a invasive approach in TUMT; patients are treated on an
better energy absorption by the prostate tissue. This ambulatory basis, complications are extremely rare and
absorption eventually causes tissue damage, which may patients suffer minimal discomfort, which arises mainly
be reflected in a change of PSA 
responders showed a significantly 
PSA level 1 week after treatment 
that of non-responders, suggesting a more pr 
effect of treatment on prostatic tissue.
Indeed, from the 20% who need catheterization for about 1 week
increase in
The results of TUMT treatment have been encourag-
ire has been some scepticism as to the place
has n mcreas m ur am ie
mg, 
of TUMT in
treatment of
urological 
. Several t
avi 
ies have
c for
s, using pressure flow analysis (PFA), in the
assessment of patients with voiding complaints. In the
that there is a significant clinical effect, with a reduction 
in symptom scores. However, the changes in Qmax are
127], amie with
PFA were not performed. Therefore, a multicentre, retro­
spective urodynamic study was conducted to evaluate 
the role of PFA in TUMT treatment to determine whether 
it can predict the clinical outcome of TUMT treatment
impressive and do not attain those achieved ;
\ The advocates of TUMT treatment have argued 
that thermotherapy eventually results in changes of 
voiding parameters after treatment comparable to those
in asymptomatic elde s respect,
C8 1. coulcl even be considered as ‘over treatment' in achieving
The role of pressure Jlow analysis
Ur amie studies have been used to investigate the
of benign prostatic disease and to evalu- 
ite the clinical outcome of various treatment modalities.
The (change of the prostatic urethra
seems to play an important role in the treatment of BPH
using TUMT [29-31]. If TUMT is able to modify the 
elasticity of the prostatic urethra, patients suffering from
asticity should be ideal candidates lor study, 
hypothesis was tested in a retrospective analysis of 
a large European multicentre study 1281, which showed
a supra-noi mux
/
c il* o
contrast to s therapy.
a
clinical results
íe in outcomeafter TUMT
variables. Recent results have produced a better under­
standing of how microwave heating of the prostate can
clinical benefits and suggest
may allow us to take advantage of the*
of a less-invasive treatment. T
seems to related to
intraprostatic temperature, which results from a complex 
interaction between the biological response to micro­
's c ! pattern ol energy provided
treatment in any individual [9,10 mac
(Ö 1995 British Journal of Uwloim 7b, S Ì 1-5 JK
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Fig. 1. Ultrasonograms of the prostate with colour Doppler mapping using the Hitachi EUB555 with a transrectal probe (V3 3W; 6.5 MHz 
multipurpose endoprobe), before (a, longitudinal and b, transverse) and immediately after TUMT (c, longitudinal and d, transverse).
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efficacy has improved and
conclusion ‘the hotter the better' seems correct. Cavities 
are frequently detected by ultrasonography after treat­
ment (Fig. 2) which may account for the improvements 
found so far. Larger prostates, with moderate to severe 
bladder outlet obstruction, seem to be the best candidates 
for the higher energy thermotherapy treatment. 
However, there is an increased morbidity, mainly arising 
from prolonged catheterization and irritative complaints 
after treatment. From these preliminary results it seems 
obvious that high-energy thermotherapy is 
forward [25].
Therefore, we conclude that the objective must be to 
determine the thermal dose which will maintain a safe 
treatment with clinically significant improvements in
;v t * ;
Xx- TV/.''. ' y :•
:%T
mm
i
-.V
SÄ
mm
■ M2
Mí.
: n .
Fig. 2. Ultrasonograms of the prostate showing cavity formation 3
months aller TUMT using the Prostatron
Transverse section, b, Longitudinal section,
2,5. a,
objective and subjective variables, whilst causing mini­
mum morbidity after treatment. Moreover, maximum 
benefit will be guaranteed only when proper selection 
criteria are identified and applied.
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